BioCentury
ARTICLE | Market Access

No surprises: CMS unveils prices for first set of IRA-negotiated drugs

Discounts range from 38% for Imbruvica to 79% for diabetes drug Januvia

August 15, 2024 9:37 PM UTC

The results from the first set of IRA negotiations are out, and the agreed prices are in line with expectations. The markets appear to have baked in the prices: None of the eight publicly traded companies with products up for negotiation saw substantial movement in their share prices. 

On Thursday, the Centers for Medicare & Medicaid Services (CMS) published its widely anticipated list of initial negotiated prices for the first cycle of 10 drugs covered under Medicare Part D. Pricing will go into effect at the start of 2026...